Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.39)
# 451
Out of 5,182 analysts
130
Total ratings
47.37%
Success rate
23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHAR Pharming Group | Initiates: Buy | $37 | $16.41 | +125.47% | 1 | Apr 10, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $14 → $17 | $6.26 | +171.57% | 12 | Apr 6, 2026 | |
| NGNE Neurogene | Maintains: Buy | $200 → $180 | $27.86 | +546.09% | 2 | Apr 6, 2026 | |
| GUTS Fractyl Health | Maintains: Buy | $8 | $0.66 | +1,120.07% | 3 | Mar 26, 2026 | |
| OCGN Ocugen | Initiates: Buy | $12 | $1.66 | +622.89% | 1 | Mar 17, 2026 | |
| WVE Wave Life Sciences | Maintains: Buy | $43 → $52 | $7.31 | +611.35% | 4 | Mar 10, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $66 → $21 | $8.76 | +139.73% | 7 | Mar 5, 2026 | |
| PASG Passage Bio | Maintains: Buy | $67 → $23 | $5.70 | +303.51% | 8 | Mar 4, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $54 → $48 | $13.35 | +259.55% | 7 | Mar 3, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $140 | $84.83 | +65.04% | 11 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $104 | $53.59 | +94.07% | 10 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $74 | $30.61 | +141.75% | 1 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $79 | $24.62 | +220.88% | 10 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $411 → $441 | $428.51 | +2.91% | 10 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $415 → $429 | $305.72 | +40.32% | 10 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $0.69 | +619.53% | 7 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $204 | $126.54 | +61.21% | 8 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $3.44 | +190.70% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $21.03 | +613.27% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $128.90 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $8.63 | +2,681.00% | 4 | Jul 23, 2019 |
Pharming Group
Apr 10, 2026
Initiates: Buy
Price Target: $37
Current: $16.41
Upside: +125.47%
Taysha Gene Therapies
Apr 6, 2026
Maintains: Buy
Price Target: $14 → $17
Current: $6.26
Upside: +171.57%
Neurogene
Apr 6, 2026
Maintains: Buy
Price Target: $200 → $180
Current: $27.86
Upside: +546.09%
Fractyl Health
Mar 26, 2026
Maintains: Buy
Price Target: $8
Current: $0.66
Upside: +1,120.07%
Ocugen
Mar 17, 2026
Initiates: Buy
Price Target: $12
Current: $1.66
Upside: +622.89%
Wave Life Sciences
Mar 10, 2026
Maintains: Buy
Price Target: $43 → $52
Current: $7.31
Upside: +611.35%
Arcturus Therapeutics Holdings
Mar 5, 2026
Maintains: Buy
Price Target: $66 → $21
Current: $8.76
Upside: +139.73%
Passage Bio
Mar 4, 2026
Maintains: Buy
Price Target: $67 → $23
Current: $5.70
Upside: +303.51%
Intellia Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $54 → $48
Current: $13.35
Upside: +259.55%
Rhythm Pharmaceuticals
Mar 2, 2026
Maintains: Buy
Price Target: $141 → $140
Current: $84.83
Upside: +65.04%
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $104
Current: $53.59
Upside: +94.07%
Feb 20, 2026
Initiates: Buy
Price Target: $74
Current: $30.61
Upside: +141.75%
Feb 18, 2026
Maintains: Buy
Price Target: $128 → $79
Current: $24.62
Upside: +220.88%
Feb 17, 2026
Maintains: Hold
Price Target: $411 → $441
Current: $428.51
Upside: +2.91%
Feb 17, 2026
Maintains: Buy
Price Target: $415 → $429
Current: $305.72
Upside: +40.32%
Dec 18, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $0.69
Upside: +619.53%
Dec 16, 2025
Maintains: Buy
Price Target: $148 → $204
Current: $126.54
Upside: +61.21%
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.44
Upside: +190.70%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $21.03
Upside: +613.27%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $128.90
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $8.63
Upside: +2,681.00%